CD272 Polyclonal Antibody

Applications

  • WB
  • IHC-P
  • IF(IHC-P)

Reactivity

  • Human
  • Mouse
  • Rat
Overview
Catalog # bs-0624R
Product Name CD272 Polyclonal Antibody
Applications WB, IHC-P, IF(IHC-P)
Reactivity Human, Mouse, Rat
Specifications
Conjugation Unconjugated
Host Rabbit
Source KLH conjugated synthetic peptide derived from human B and T-lymphocyte attenuator
Immunogen Range 239-289/289
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months.
Target
Gene ID 151888
Swiss Prot Q7Z6A9
Subcellular location Cytoplasm
Synonyms BTLA1; CD272; B- and T-lymphocyte attenuator; B- and T-lymphocyte-associated protein; BTLA
Background B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Application Dilution
WB 1:300-1000
IHC-P 1:200-400
IF(IHC-P) 1:50-200